Introduction

The autumn of 2025 brought a notable change to menopausal care in England: a new non‑hormonal option, Veoza, was approved for NHS use for women with problematic hot flushes and night sweats when HRT is unsuitable. That decision — estimated to affect as many as 500,000 women — has refocused attention on non‑hormonal support at a time when many are already exploring complementary approaches, including low‑dose CBD and other hemp‑derived cannabinoids.

This article explains what we know so far, how the evidence is evolving, and practical considerations for UK women who are curious about microdosing cannabinoids for hot flushes, night sweats, sleep and mood. It is intended to inform, not to prescribe — always discuss changes with your GP or menopause specialist.

What has changed: Veoza, NICE guidance and the context for non‑hormonal care

In late 2025 the NHS in England approved Veoza as a non‑hormonal drug option for menopausal hot flushes and night sweats when HRT is unsuitable, and commentators have suggested around half a million women could benefit (BBC, 2025). At the same time, clinical bodies such as NICE and the British Menopause Society continue to position HRT as first‑line treatment, while updating guidance and consensus statements to clarify non‑hormonal options and when they are appropriate (NICE; BMS, 2025).

Importantly, NHS patient materials and charities like Women’s Health Concern still promote a range of non‑hormonal choices — SSRIs/SNRIs, clonidine, CBT and other supportive therapies — for people who cannot, or choose not to, take HRT. Many women are also exploring unregulated complementary options such as hemp‑derived CBD products alongside conventional care.

How common are menopausal symptoms and why alternatives matter

Menopausal symptoms are very common: roughly 80% of women experience some symptoms during the transition and around a quarter describe them as severe. That scale explains the appetite for safe, well‑tolerated alternatives for those who either cannot have HRT or prefer non‑hormonal approaches (Royal United Hospitals/BJOG summaries, 2025).

What the evidence says about low‑dose CBD and other hemp cannabinoids

Research into hemp‑derived cannabinoids for menopause is active and growing. Several early‑phase trials, including phase‑2 studies, are underway and some preliminary reports suggest that many women report symptom benefit — particularly for sleep, anxiety and overall wellbeing. However, the body of robust, long‑term clinical evidence specifically addressing hot flushes and night sweats remains limited (trial listings and phase‑2 summaries, 2024–2026).

Key points from the emerging evidence base:

• Signals, not certainties: Small trials and observational reports offer encouraging signals for symptom relief (sleep, mood, sleep continuity), but they do not yet provide definitive proof that cannabinoids are effective for menopausal vasomotor symptoms.
• Many women report subjective benefit: Patient surveys and clinic reports show growing demand and anecdotal reports of improvement in sleep and anxiety during the menopause transition (Cannabis Health News, 2025).
• Safety profile: Short‑term use of purified CBD is generally considered well tolerated in studies to date, but long‑term safety, the best low‑dose regimens for menopause, and comprehensive interaction data remain incomplete.

Forms and microdosing: practical options women are choosing

Women interested in trying hemp‑derived cannabinoids often favour low‑dose or microdosing strategies aimed at subtle, nightly or daytime support rather than large therapeutic doses. Common formats include sublingual drops, syrups, microdose gummies and drink enhancers — each offering different onset times and dosing control.

Examples of product types women mention include sublingual oils for flexible low dosing such as Wylde Natural Cold‑Pressed Drops 1000mg CBD Oil 10ml, night‑oriented formulas for sleep like OTO 10 CBD Sleep Drops or CBD Living PM Syrup, conservative microdose edibles like Wylde CBD Gummy Bears 30x 10mg CBD per bear Full Spectrum, or subtle daily boosts such as a CBD Drinks Enhancer.

Microdosing often means starting very low (for example single‑digit mg ranges), observing effects for several days, and adjusting slowly. Many users track sleep quality, flush frequency and mood to decide if a given approach feels helpful.

Safety, interactions and the need for clinical conversation

While CBD is commonly perceived as benign, there are important safety considerations. Early trial reports and reviews note that long‑term safety and detailed drug‑interaction profiles are still incomplete. CBD can affect liver enzymes that metabolise other medicines, so combining cannabinoids with prescribed drugs — including some antidepressants, anticoagulants and other common medications — should only be done after discussing risks with a GP or pharmacist.

Practically speaking:

• Talk with your GP or menopause specialist before starting any CBD product, particularly if you take other medications.
• Start low and go slow: low‑dose strategies minimise the chance of side effects and make it easier to spot interactions.
• Choose quality‑assured products from reputable suppliers and check batch testing where available.
• Be cautious about combining unregulated CBD with prescription non‑hormonal drugs such as Veoza without clinical advice.

Where CBD fits among other non‑hormonal options

NICE, the BMS and patient organisations continue to recommend established non‑hormonal treatments where appropriate — medications, clonidine, psychological approaches like CBT, lifestyle changes and sleep hygiene. Hemp‑derived cannabinoids are best viewed as complementary options that some women find helpful for sleep, relaxation and mood support, rather than replacements for evidence‑based medical treatments.

Conclusion

The arrival of Veoza on the NHS for women who cannot use HRT is an important development that expands formal non‑hormonal choices. At the same time, patient interest in low‑dose CBD and other hemp‑derived cannabinoids is growing, driven by early positive reports and an understandable desire for tolerable, lifestyle‑friendly options.

Current evidence is promising but incomplete: ongoing phase‑2 studies will help clarify benefits and safe dosing for menopausal symptoms. Until stronger data are available, the safest path is an informed, measured approach — discuss interest with your GP, consider established non‑hormonal therapies where suitable, and if you try low‑dose CBD start low, monitor effects and choose high‑quality products.

Menopause care is increasingly personalised. For some, a carefully considered hemp‑derived supplement may offer gentle support alongside conventional treatments and lifestyle measures; for others, medically approved options such as HRT or newly available NHS therapies will remain preferable. The best outcomes start with an open conversation with your healthcare provider and a cautious, evidence‑aware mindset.